Enfermedad pulmonar intersticial fibrosante progresiva (EPI-FP)

 

Effect of nintedanib on progression of interstitial lung disease (ILD) in patients with autoimmune disease-related ILDs: further data from the INBUILD trial

Matteson et al.

 

Acceder

Nintedanib dose adjustments and adverse events in patients with progressive autoimmune disease-related interstitial lung diseases in the INBUILD trial

Volkmann et al.
 

Acceder

Efficacy and safety of nintedanib in patients with autoimmune disease-related interstitial lung disease treated with DMARDs and/or glucocorticoids at baseline

Aringer et al.
 

Acceder

¿Te ha resultado útil esta información?